Protection with only a few injections per year instead of weekly or monthly dosing
For the roughly one in fifty people who navigate daily life under the shadow of peanut allergy, the margin between a meal and a medical emergency has long been uncomfortably thin. A Swiss biotechnology firm, Mabylon AG, has now crossed a quiet but consequential threshold — dosing the first human participant in a trial of MY006, a tri-specific monoclonal antibody designed not to manage allergic reactions after they strike, but to prevent them from occurring at all. Derived from the immune cells of allergic patients themselves, the drug represents a philosophical shift in how medicine might approach the body's misdirected defenses: not suppression after the fact, but interception before the cascade begins.
- Peanut allergy affects millions in the U.S. and Europe, and for those living with it, a single accidental exposure can trigger anaphylactic shock — a potentially fatal emergency that no amount of vigilance fully eliminates.
- Existing treatments demand relentless commitment — weekly injections, daily pills, or months-long desensitization regimens that carry their own risks — leaving patients without a simple, durable solution.
- MY006 targets all three major peanut allergens simultaneously and is engineered to persist in the bloodstream long enough that just two to four injections per year could sustain protection.
- Mabylon has now administered the first human dose, with the trial enrolling healthy adults first, then moving to allergic patients aged 12 to 55 across specialized U.S. allergy centers.
- The FDA's prior clearance of the investigational application signals regulatory confidence in the science, marking Mabylon's transition from research firm to clinical-stage company.
A Swiss biotechnology company has taken its peanut allergy drug into human testing for the first time. Mabylon AG announced on December 11 that the first volunteer had received MY006, a monoclonal antibody engineered from human immune cells to recognize and neutralize the three proteins most responsible for triggering peanut reactions.
The trial unfolds in two stages. The first enrolls up to 32 healthy adults across four cohorts, testing escalating single doses delivered by subcutaneous injection before moving to multiple doses at the highest tolerated level. The second stage introduces up to 16 adolescents and adults aged 12 to 55 who actually have peanut allergies, allowing researchers to observe the drug's performance in immune systems already primed to react. The study is fully randomized and blinded, with neither participants nor researchers knowing who receives the drug versus placebo.
What sets MY006 apart is its architecture. Where current therapies demand frequent dosing and address one target at a time, MY006 was designed to linger in the bloodstream and block three allergens simultaneously — potentially reducing treatment to just two to four injections per year. The antibody was reverse-engineered from immune cells of allergic patients, then refined in the lab to work more precisely and last longer.
The stakes are real. Peanut allergy affects one to two percent of people in the U.S. and Europe, and accidental exposure can cause anaphylactic shock — a whole-body emergency requiring immediate intervention. Those living with the condition must scrutinize every label and every meal, knowing a single lapse could be catastrophic. Current approaches manage reactions or slowly desensitize patients over months; MY006 is conceived as a preventive, something taken before exposure to stop the allergic cascade entirely.
The trial will first assess safety and tolerability, then track how long the drug persists in the body and whether the immune system develops resistance to it. In the patient cohort, researchers will begin to learn whether MY006 actually prevents or reduces allergic reactions. Those answers will take months to emerge — but with the first dose now given, the work of proving whether this approach can change the landscape of allergy management has formally begun.
A Swiss biotechnology company has dosed the first participant in a clinical trial of a drug designed to prevent peanut allergies before they happen. Mabylon AG announced on December 11 that the initial volunteer in the study had received MY006, a monoclonal antibody engineered from human immune cells and built to recognize and neutralize the three major proteins that trigger peanut reactions.
The trial itself is structured in two phases. The first part enrolls up to 32 healthy adults between 18 and 55 years old across four cohorts, testing increasing single doses of the drug delivered by injection under the skin, then moving to multiple doses at the highest safe level. The second part will bring in up to 16 adolescents and adults aged 12 to 55 who actually have peanut allergies, allowing researchers to watch how the drug performs in people whose immune systems are primed to react. One clinical site is handling the healthy volunteer portion; several specialized allergy centers across the United States are managing the patient portion. The study is randomized, blinded on all sides, and controlled against placebo, meaning neither the participants nor the researchers know who is getting the real drug.
What makes MY006 different from existing allergy treatments is its design. Most current therapies require frequent dosing—weekly or monthly injections, or daily pills. MY006 is engineered to stay in the bloodstream longer and to hit three allergen targets at once rather than one. The company says patients might need only two to four injections per year to maintain protection. The antibody was derived from allergic patients themselves, meaning it was reverse-engineered from immune cells that naturally learned to fight peanut proteins, then refined in the lab to work better and last longer.
Peanut allergy is not a minor concern. Between one and two percent of people in the United States and Europe live with it, and it carries real danger. Accidental exposure can trigger anaphylactic shock, a potentially fatal whole-body reaction that requires immediate emergency treatment. People with peanut allergies must read every label, ask about ingredients at restaurants, and live with the knowledge that a single mistake could be catastrophic. Current treatments focus on managing reactions after they happen or gradually desensitizing patients through repeated small exposures—a process that takes months and carries its own risks. MY006 is being developed as a preventive, something you take before exposure to block the allergic cascade entirely.
Mabylon, based in the Zurich area, specializes in extracting antibodies from human sources rather than engineering them from scratch or borrowing them from animals. The company's leadership framed the trial's start as a milestone. The FDA had already cleared the investigational new drug application, a regulatory green light that meant the agency believed the science was sound enough to test in people. For Mabylon, this marks the transition from a research company to a clinical-stage company—the moment when a drug candidate moves from the lab into human bodies.
The trial will measure safety first, watching for side effects and how well the drug is tolerated at the injection site. It will track pharmacokinetics, the drug's journey through the body and how long it persists. It will look for immunogenicity, whether the body develops antibodies against the drug itself, which could neutralize it over time. And in the patient portion, researchers will begin to see whether MY006 actually prevents allergic reactions, whether it reduces their severity, or whether it fails to work as designed. Those answers will take months to accumulate. But with the first dose now administered, the long process of proving whether this approach can reshape how peanut allergy is managed has officially begun.
Citas Notables
By dosing the first participant, we are one step closer to potentially delivering a prophylactic therapy that could safeguard patients from the risks of accidental peanut exposure.— Peter Lichtlen, Chief Medical Advisor, Mabylon AG
MY006 is a human-derived monoclonal antibody with high-affinity binding to the three major peanut allergens. Its tri-specific format allows for simultaneous recognition of non-overlapping epitopes across multiple allergens.— Dr. Niccolò Pengo, Chief Scientific Officer, Mabylon AG
La Conversación del Hearth Otra perspectiva de la historia
Why does a drug that prevents allergies need to be tested in healthy people first if the goal is to help allergic patients?
Safety comes before efficacy. You need to know the drug doesn't cause unexpected harm in people without the disease before you give it to people whose immune systems are already in a heightened state. A healthy volunteer's body is a cleaner baseline.
The drug targets three allergens at once. Why is that better than targeting one?
Peanut allergies aren't simple. Different people react to different proteins within the peanut, and some people react to multiple ones. A drug that hits only one target might work for some patients and miss others entirely. Three targets means broader coverage across the allergic population.
Two to four injections a year sounds remarkable compared to weekly or monthly treatments. How is that possible?
The antibody was engineered to stay in the bloodstream much longer than natural antibodies do. It's a durability problem solved through protein engineering. The longer it circulates, the longer it protects, and the less often you need to inject it.
Is there a risk that the body will reject the drug over time?
That's exactly what the trial is watching for. If your immune system decides MY006 is a foreign invader, it will make antibodies against the antibody itself, neutralizing it. That's immunogenicity. If it happens, the drug stops working. The trial will tell us whether that's a real problem.
Why does it matter that these antibodies came from allergic patients rather than being designed from scratch?
Allergic patients' immune systems have already solved the puzzle of recognizing peanut proteins. By extracting antibodies from people who naturally developed them, you're starting with a solution that actually works in human biology. You're not guessing; you're copying nature and then improving it.